Cerevel Therapeutics Holdings (CERE) Receives a Hold from Goldman Sachs

In a report released today, Madhu Kumar from Goldman Sachs maintained a Hold rating on Cerevel Therapeutics Holdings (CEREResearch Report), with a price target of $20.00. The company’s shares closed last Monday at $25.21.

According to TipRanks.com, Kumar is a 5-star analyst with an average return of 17.3% and a 48.1% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Iovance Biotherapeutics, and Arvinas Holding Company.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cerevel Therapeutics Holdings with a $42.60 average price target.

See the top stocks recommended by analysts >>

Cerevel Therapeutics Holdings’ market cap is currently $3.74B and has a P/E ratio of -14.73.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ARYA Sciences Acquisition Corp II is a blank check company.

Read More on CERE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed